Literature DB >> 20057491

Parkinson disease: Another player in gene therapy for Parkinson disease.

Michael G Kaplitt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20057491     DOI： 10.1038/nrneurol.2009.214

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.

Authors:  Yilong Ma; Andrew Feigin; Vijay Dhawan; Masafumi Fukuda; Qiuhu Shi; Paul Greene; Robert Breeze; Stanley Fahn; Curt Freed; David Eidelberg
Journal:  Ann Neurol       Date:  2002-11       Impact factor: 10.422

2.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

Authors:  C R Freed; P E Greene; R E Breeze; W Y Tsai; W DuMouchel; R Kao; S Dillon; H Winfield; S Culver; J Q Trojanowski; D Eidelberg; S Fahn
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

3.  Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

Authors:  Béchir Jarraya; Sabrina Boulet; G Scott Ralph; Caroline Jan; Gilles Bonvento; Mimoun Azzouz; James E Miskin; Masahiro Shin; Thierry Delzescaux; Xavier Drouot; Anne-Sophie Hérard; Denise M Day; Emmanuel Brouillet; Susan M Kingsman; Philippe Hantraye; Kyriacos A Mitrophanous; Nicholas D Mazarakis; Stéphane Palfi
Journal:  Sci Transl Med       Date:  2009-10-14       Impact factor: 17.956

4.  Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.

Authors:  Krystof S Bankiewicz; Marcel Daadi; Philip Pivirotto; John Bringas; Laura Sanftner; Janet Cunningham; John R Forsayeth; Jamie L Eberling
Journal:  Exp Neurol       Date:  2005-12-09       Impact factor: 5.330

5.  Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.

Authors:  Shin-Ichi Muramatsu; Ken-Ichi Fujimoto; Kunihiko Ikeguchi; Nami Shizuma; Katsuyoshi Kawasaki; Fumiko Ono; Yang Shen; Lijun Wang; Hiroaki Mizukami; Akihiro Kume; Masaru Matsumura; Ikuko Nagatsu; Fumi Urano; Hiroshi Ichinose; Toshiharu Nagatsu; Keiji Terao; Imaharu Nakano; Keiya Ozawa
Journal:  Hum Gene Ther       Date:  2002-02-10       Impact factor: 5.695

6.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

Authors:  William J Marks; Jill L Ostrem; Leonard Verhagen; Philip A Starr; Paul S Larson; Roy Ae Bakay; Robin Taylor; Deborah A Cahn-Weiner; A Jon Stoessl; C Warren Olanow; Raymond T Bartus
Journal:  Lancet Neurol       Date:  2008-04-02       Impact factor: 44.182

7.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

Authors:  C W Christine; P A Starr; P S Larson; J L Eberling; W J Jagust; R A Hawkins; H F VanBrocklin; J F Wright; K S Bankiewicz; M J Aminoff
Journal:  Neurology       Date:  2009-10-14       Impact factor: 9.910

8.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Authors:  Michael G Kaplitt; Andrew Feigin; Chengke Tang; Helen L Fitzsimons; Paul Mattis; Patricia A Lawlor; Ross J Bland; Deborah Young; Kristin Strybing; David Eidelberg; Matthew J During
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

9.  A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

Authors:  C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422
  9 in total
  6 in total

1.  Lentiviral vector mediates exogenous gene expression in adult rat DRG following peripheral nerve remote delivery.

Authors:  Ping Yang
Journal:  J Mol Neurosci       Date:  2012-02-09       Impact factor: 3.444

Review 2.  Disease modification in Parkinson's disease.

Authors:  Claire Henchcliffe; W Lawrence Severt
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

3.  Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  Ashley S Harms; Christopher J Barnum; Kelly A Ruhn; Steve Varghese; Isaac Treviño; Armin Blesch; Malú G Tansey
Journal:  Mol Ther       Date:  2010-10-19       Impact factor: 11.454

Review 4.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

5.  Fabrication of Positively Charged Fluorescent Polymer Nanoparticles for Cell Imaging and Gene Delivery.

Authors:  Lin Wei; Di Zhang; Xuanfang Zheng; Xuyao Zeng; Youlin Zeng; Xinbo Shi; Xin Su; Lehui Xiao
Journal:  Nanotheranostics       Date:  2018-02-15

Review 6.  The current status of gene therapy for Parkinson's disease.

Authors:  Shin-Ichi Muramatsu
Journal:  Ann Neurosci       Date:  2010-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.